April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group,…
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies…
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for…
TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…
Upcoming free, educational webinars from Xtalks will feature topics biomarkers, cell and gene therapy, clinical trials, drug discovery & development,…
Unveiled at SCOPE Summit, The Virtual Solution Leverages Real-World EHR Data to Quantify Patient-Level Competition and Eligibility Before Protocol LockBOSTON,…
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- ProofPilot, the leading solution to create simple and predictable clinical trials, is proud to…
Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapyFindings to inform ethical guidelines, future clinical…
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to…